• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Gardasil versus GAVI versus Public Health and Safety

Gardasil versus GAVI versus Public Health and Safety

June 1, 2012 By Norma Leave a Comment

[SaneVax: A recent article in The Stanford Journal of Public Health fails to address multiple public health issues regarding the introduction of HPV vaccines in developing countries. What are the future consequences to public health when introducing HPV vaccines into the adolescent population of countries that do not currently have cervical cancer screening programs, particularly when these vaccines do not eliminate the need for screening? What are the future health consequences when introducing HPV vaccines into a population with no way to test for prior exposure to to the purported pathogen? What are the potential consequences of introducing a vaccine to a population with no means of establishing an individual’s medical history?

These are but a few of the questions left unanswered in this ‘journal of public health.’ It appears this journal is more interested in HPV vaccine uptake, than any real public health issues. Once again, medical consumers are on their own. This is not acceptable in any country – much less developing countries without access to adequate healthcare. Would it not make more sense to establish adequate medical facilities first?]

Gardasil versus GAVI: Challenges to Implementing HPV Vaccines in Developing Countries

By Christina Averhoff

HPV Vaccines versus Public Health

Cervical cancer, caused by human papillomavirus (HPV), is one of few preventable cancers. In the developed world, this cancer is relatively easy to manage with preventative surgery or HPV vaccines such as Gardasil. However, in the developing world, cervical cancer is a virulent threat consistently ranking among the leading causes of death in women.1 HPV causes approximately 275,000 deaths due to cervical cancer each year, 88% of which occur in developing countries.2 If available around the world, the HPV vaccine could decrease rates of cervical cancer by 70%.2

The Global Alliance for Vaccines and Immunizations (GAVI) was launched in early 2000 to support the implementation of vaccination programs to reduce child mortality rates in 70 of the world’s poorest countries.3 GAVI gathers funds from donors worldwide, and decides which vaccines would be the most efficacious and cost-effective to introduce to these countries. Recently, GAVI has agreed to fund the HPV vaccine. This decision will likely protect two million women in nine countries from cervical cancer by 2015.2Although GAVI has agreed to fund this vaccine, impediments to introduction of the vaccine may still exist, says Dr. Lauri Markowitz, an expert on HPV and STIs at the Center for Disease Control and Prevention (CDC).4GAVI may cover the costs for vaccines and some operational costs, but the states are responsible for delivering them in the most effective and efficient way. Introduction of vaccine requires capacity for storage, transport, and personnel, which might be lacking in the country, adds Markowitz, further complicating the launch of the vaccine program. Due to infrastructure and capacity issues, many GAVI countries may delay the introduction of this vaccine.

Read the entire article here.

Related

Filed Under: HPV, Vaccine Marketing, World News Tagged With: GAVI, HPV VACCINES, public health and safety

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

My Personal Battle After Gardasil

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

hpv vaccine side effects

Welcome to Year 8 – are HPV vaccine side effects “quite mild”?!

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in

 

Loading Comments...